GERMANY – Bayer has hired an oncology leader from GlaxoSmithKline for the second time this year, appointing Tara Frenkl, to lead oncology development for its oncology strategic business unit. Tara…
Read MoreTag: Bayer
Bayer invests to drive breakthrough innovations in the life sciences
GERMANY – Bayer has announced plans to invest more than €1.3 billion (US$1.4 billion) in its Leaps by Bayer impact investment unit over the next three years at its first…
Read MoreBayer announces changes in executive leadership team of Crop Science division
GERMANY – Bayer has announced changes to its Crop Science division’s leadership team, with Kelly Gast taking over as Chief Financial Officer (CFO) from Michael A. Schulz on April 1,…
Read MoreBayer’s breakthrough innovative approach in healthcare transforms pharma business
GERMANY – Bayer has presented the latest developments in the ongoing transformation of its pharmaceuticals business at its annual Pharma Media Day 2022, with the goal of delivering long-term, sustainable…
Read MoreLilly, Evotec partner to develop drugs for metabolic diseases
USA – Eli Lilly and Company has announced a drug discovery collaboration with Evotec in the field of metabolic diseases, with a focus on kidney diseases and diabetes. The three-year…
Read MoreBayer in gene editing tech deal with Mammoth Biosciences
GERMANY – Bayer and Mammoth Biosciences have announced an agreement to use the latter’s CRISPR systems to develop in vivo gene-editing therapies, with an initial focus on liver-targeted diseases. Bayer…
Read MoreCipla acquires one-third stake in Clean Max Auriga Power
INDIA – Cipla announced the acquisition of up to a 33% partnership interest in Clean Max Auriga Power in a deal that will see the latter become an associate of…
Read MoreDunad Therapeutics, Novartis in strategic deal to develop novel Targeted Protein degrader
UNITED KINGDOM – Dunad Therapeutics, a biopharmaceutical company focused on developing next-generation targeted protein degradation therapies, has announced a strategic collaboration and license agreement with Novartis to develop orally bioavailable…
Read MoreAI giant Exscientia files IPO, raises over US$460 million for drug research and development
UNITED KINGDOM – Exscientia’s initial public offering and private placement has raised US$464 million to fund its artificial intelligence-based approach to drug discovery and development. The new cash infusion follows…
Read MoreUCTD, Bayer’s consumer health division sign OTC distribution pact
EGYPT – Dr. Mohamed Galal, Vice President & Head of Bayer Consumer Health Division – Middle East, and Mr. Ayman Hossam Omar, Chief Executive Officer of United Company for Trading…
Read More